Invokana (Canagliflozin): Uses, Side Effects, and Prescription Safety

Invokana (canagliflozin) is a prescription medicine in the sodium-glucose cotransporter 2, or SGLT2, inhibitor class. It is used to improve blood sugar control in people with type 2 diabetes and, in selected adults, to reduce certain cardiovascular and kidney risks. Current U.S. prescribing information also includes use in children aged 10 years and older with type 2 diabetes for glycemic control. Canagliflozin works mainly through the kidneys, causing more glucose to leave the body in urine rather than remain in the bloodstream. This mechanism can provide benefits beyond glucose lowering in some people with cardiovascular disease or diabetic kidney disease, but it also creates distinctive risks such as genital infections, dehydration, ketoacidosis, and urinary problems. Invokana is therefore not simply a “sugar-lowering tablet”; kidney function, other medicines, foot health, hydration, and individual medical history all matter. This guide explains what Invokana is used for, how it works, typical prescription dosing, side effects, and the safety issues patients should understand.

What Is Invokana Used For?
Invokana contains canagliflozin, an SGLT2 inhibitor approved for several specific uses in type 2 diabetes.
According to the current U.S. label, Invokana is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children aged 10 years and older with type 2 diabetes. In adults, it is also approved to reduce major cardiovascular events in people with type 2 diabetes and established cardiovascular disease, and to reduce certain kidney and cardiovascular outcomes in people with diabetic nephropathy and significant albuminuria.
The current FDA-approved Invokana prescribing information describes these indications and the latest safety and dosing requirements.
Can Invokana lower blood sugar?
Yes. Canagliflozin lowers blood glucose by reducing the kidney's reabsorption of filtered glucose.
More glucose is therefore excreted in urine. This effect is partly dependent on kidney function, which is why its glucose-lowering effect becomes weaker as estimated glomerular filtration rate, or eGFR, declines.
Invokana is intended for type 2 diabetes rather than routine treatment of type 1 diabetes.
Can Invokana protect the heart?
In selected adults with type 2 diabetes and established cardiovascular disease, canagliflozin is approved to reduce the risk of major adverse cardiovascular events, including cardiovascular death, nonfatal heart attack, and nonfatal stroke.
Current American Diabetes Association guidance recommends an SGLT2 inhibitor with demonstrated cardiovascular benefit for many people with type 2 diabetes who also have established cardiovascular disease, chronic kidney disease, or substantial cardiovascular risk.
The 2026 ADA cardiovascular disease recommendations for diabetes support the broader role of SGLT2 inhibitors in cardiovascular risk reduction when clinically appropriate.
Can Invokana help protect the kidneys?
Yes, in a defined group of adults with type 2 diabetes and diabetic kidney disease.
Invokana is approved to reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with diabetic nephropathy and albuminuria greater than 300 mg per day.
The 2026 ADA Standards of Care also recommend SGLT2 inhibitors with demonstrated benefit for many people with type 2 diabetes and chronic kidney disease because they can slow kidney disease progression and reduce cardiovascular events.
How Does Canagliflozin Work, and What Benefits Can It Provide?
Canagliflozin blocks SGLT2 proteins in the proximal tubules of the kidneys. These proteins normally reclaim much of the glucose filtered into urine.
When SGLT2 is inhibited, more glucose and some sodium remain in the urine and are excreted.
Why does this lower blood sugar?
Removing glucose through urine reduces the amount of glucose circulating in the blood.
Unlike insulin or sulfonylureas, this effect does not primarily depend on forcing the pancreas to release more insulin. For that reason, SGLT2 inhibitors by themselves generally have a relatively low risk of hypoglycemia, although low blood sugar can occur when they are combined with insulin or insulin-secretagogue medicines.
Can Invokana cause weight loss?
Some people lose modest weight while taking an SGLT2 inhibitor because calories are lost in urinary glucose.
However, Invokana is not approved as a general weight-loss medicine, and treatment should not be started solely for cosmetic weight reduction.
Any change in weight should be considered alongside diabetes control, kidney function, hydration, cardiovascular risk, and adverse effects.
Does kidney protection depend only on lowering glucose?
No. SGLT2 inhibitors appear to provide kidney benefits through several mechanisms beyond glucose lowering, including effects on pressure within the kidney's filtering units and sodium handling.
The 2026 ADA kidney-disease guidance notes that SGLT2 inhibitors can reduce albuminuria and slow loss of kidney function through mechanisms that are not entirely dependent on glucose lowering.
Invokana can do more than reduce blood glucose in selected people with type 2 diabetes. Its cardiovascular and kidney benefits are clinically important, but the medicine must be matched to the patient's kidney function, vascular risk, hydration status, other medicines, and potential adverse effects.
Main established uses and potential benefits of Invokana
Clinical situation | Role of Invokana | Important context |
Type 2 diabetes | Improves glycemic control | Used with diet, exercise, and individualized diabetes care |
Type 2 diabetes with established cardiovascular disease | Reduces risk of major cardiovascular events | Approved adult indication |
Diabetic nephropathy with significant albuminuria | Reduces selected kidney and cardiovascular outcomes | Approved for defined adult patients |
Heart-failure risk in diabetic kidney disease | Can reduce hospitalization for heart failure | Benefit demonstrated in kidney-outcomes research |
Type 1 diabetes | Not recommended for glycemic control | Ketoacidosis risk is substantially higher |
Weight management alone | Not an approved indication | Any weight loss is secondary to its metabolic action |
What Is the Usual Invokana Dosage?
The current U.S. label recommends starting Invokana at 100 mg once daily before the first meal of the day for glycemic control in adults and children aged 10 years and older with type 2 diabetes.
In patients who tolerate 100 mg, have an eGFR of at least 60 mL/min/1.73 m², and require additional glucose lowering, the dose can be increased to 300 mg once daily.
For its cardiovascular and kidney-risk indications in adults, the current label recommends 100 mg once daily.
Why does kidney function affect dosing?
Canagliflozin acts through the kidneys, so eGFR influences both effectiveness and safety.
For people with an eGFR from 30 to below 60 mL/min/1.73 m², the current U.S. label limits the maximum dose to 100 mg once daily. Starting treatment at an eGFR below 30 is generally not recommended, although some adults already taking 100 mg who have substantial albuminuria may continue it for kidney and cardiovascular protection.
Does everyone need 300 mg for better results?
No.
The 300 mg dose is used only in selected patients who need additional glycemic control, tolerate the lower dose, and have sufficient kidney function. A higher dose does not automatically provide greater cardiovascular or kidney protection.
Do not increase from 100 mg to 300 mg without a prescriber reviewing kidney function and treatment goals.
Why is Invokana stopped before some procedures?
SGLT2 inhibitors can increase the risk of ketoacidosis during fasting, severe illness, or surgery.
The current Invokana label recommends withholding the medicine for at least three days, when possible, before surgery or procedures associated with prolonged fasting.
Restarting should be guided by the treating clinician once the person is medically stable and eating normally.
General Invokana dosage information from current U.S. prescribing guidance
Situation | General labeled approach | Important note |
Starting dose for glycemic control | 100 mg once daily before first meal | Kidney function should be assessed first |
Additional glycemic control | May increase to 300 mg once daily | Requires eGFR ≥60 and good tolerance |
eGFR 30 to <60 | Maximum 100 mg once daily | Glucose-lowering effect may be reduced |
eGFR <30 | Initiation generally not recommended | Selected adults with albuminuria may continue 100 mg for kidney/CV benefit |
Cardiovascular indication | 100 mg once daily | Adult indication |
Kidney-risk indication | 100 mg once daily | Adult diabetic nephropathy with specified albuminuria |
Before prolonged fasting or surgery | Withhold at least 3 days when possible | Helps reduce ketoacidosis risk |
This table summarizes current U.S. labeling and is not a personalized prescription.
What Are the Common Side Effects of Invokana?
The most common adverse reactions reported in current prescribing information are female genital fungal infections, urinary tract infections, and increased urination.
These effects make sense biologically because canagliflozin increases glucose in urine, which changes the urinary and genital environment.
Why can genital yeast infections occur?
Higher urinary glucose can encourage fungal growth around the genital area.
Symptoms can include itching, irritation, redness, soreness, or abnormal discharge. Genital fungal infections can occur in both women and men, although they are reported particularly often in women.
Recurrent symptoms should be discussed with a healthcare professional rather than repeatedly self-treated without reviewing whether Invokana is contributing.
Can Invokana cause dehydration or low blood pressure?
Yes.
Because canagliflozin increases urinary glucose and fluid loss, it can reduce circulating blood volume. This may cause dizziness, weakness, low blood pressure, or kidney problems, particularly in older adults, people with impaired kidney function, or those taking loop diuretics.
Adequate hydration and medication review are especially important during hot weather, vomiting, diarrhea, or other illnesses that cause fluid loss.
Can Invokana cause low blood sugar?
By itself, canagliflozin usually has a relatively low hypoglycemia risk.
However, the risk rises when Invokana is used with insulin or medicines that stimulate insulin release, such as sulfonylureas.
Current labeling advises clinicians to consider reducing those medicines when necessary to lower hypoglycemia risk.
Which Serious Invokana Risks Need Special Attention?
Several uncommon but clinically important problems require more attention than ordinary side effects.
Current Invokana labeling warns about ketoacidosis, lower-limb amputation, volume depletion, serious genitourinary infections, hypoglycemia with some combination therapies, hypersensitivity reactions, and bone fracture.
What is diabetic ketoacidosis with Invokana?
Ketoacidosis is a dangerous buildup of ketones and acids in the blood.
SGLT2-associated ketoacidosis can sometimes occur even when blood glucose is not extremely high. Warning symptoms include nausea, vomiting, abdominal pain, marked tiredness, and labored or difficult breathing.
Risk can increase during acute illness, prolonged fasting, a ketogenic diet, missed or reduced insulin, dehydration, surgery, pancreatic disease, or heavy alcohol use.
What is the amputation risk?
Canagliflozin previously carried an FDA Boxed Warning about lower-limb amputation. In 2020, the FDA removed that Boxed Warning after reviewing newer data showing that cardiovascular and kidney benefits had become clearer and the amputation risk appeared lower than previously described when patients were appropriately monitored.
The risk was not declared nonexistent. Current Invokana labeling still advises monitoring for lower-limb infections and ulcers.
The FDA update on canagliflozin and lower-limb amputation risk explains why the Boxed Warning was removed while foot monitoring remained important.
What is Fournier's gangrene?
Fournier's gangrene is a rare but severe infection of the tissues around the genital or perineal area.
Current Invokana labeling instructs clinicians to urgently evaluate pain, tenderness, redness, or swelling in that region when accompanied by fever or feeling unwell. Suspected cases require discontinuation and immediate medical and surgical treatment.
Although rare, this complication is potentially life-threatening.
What Should Be Checked Before and During Invokana Treatment?
Kidney function and hydration status should be assessed before treatment begins.
The current label recommends checking renal function before starting Invokana and periodically afterward, and correcting volume depletion before initiation.
Which other medicines can affect safety?
A full medication review matters because Invokana is often prescribed alongside several other diabetes, blood-pressure, heart, or kidney medicines.
Particular attention is needed with:
insulin or sulfonylureas, because hypoglycemia risk may increase;
loop diuretics, because dehydration and low blood pressure may become more likely;
medicines that influence canagliflozin metabolism; and
treatments that may already affect kidney function or fluid status.
The current label also contains dosage-modification instructions for certain UGT enzyme inducers.
Does taking Invokana mean kidney tests are no longer needed?
No.
Even though canagliflozin can protect kidney function in selected patients, kidney monitoring remains important. The prescriber uses eGFR, albuminuria, hydration status, and other laboratory results to decide whether the medicine remains appropriate.
ADA 2026 guidance recommends SGLT2 inhibitors with proven benefit for many people with type 2 diabetes and CKD, while still emphasizing individualized kidney-risk management.
The 2026 ADA chronic kidney disease guidance for diabetes provides current recommendations for SGLT2 inhibitor use in type 2 diabetes with CKD.
What about pregnancy and breastfeeding?
Current Invokana labeling advises about potential fetal risk, particularly during the second and third trimesters of pregnancy, and does not recommend use while breastfeeding.
Anyone who is pregnant, planning pregnancy, or breastfeeding should discuss alternative diabetes treatment with the prescribing clinician rather than stopping medication without a replacement plan.
Safety: When Should You Seek Medical Care?
Stop Invokana and seek urgent medical assessment if symptoms suggest ketoacidosis, including nausea, vomiting, abdominal pain, unusual exhaustion, or difficult breathing—especially during illness, fasting, dehydration, or after a major reduction in insulin. Ketoacidosis can occur even without extremely high blood glucose.
Prompt medical care is also needed for severe genital or perineal pain and swelling with fever, inability to maintain fluids, fainting or severe dizziness, rapidly worsening foot ulcers or infections, or symptoms of a serious allergic reaction.
People with peripheral artery disease, previous amputation, neuropathy, diabetic foot ulcers, or recurrent lower-limb infections should pay particular attention to foot care. The FDA removed canagliflozin's amputation Boxed Warning in 2020, but continued to advise preventive foot care and monitoring because the risk remains clinically relevant.
During severe illness, fasting, or surgery, do not independently decide whether to continue the medicine. A clinician may temporarily hold Invokana to reduce ketoacidosis or dehydration risk.
Conclusion
Invokana (canagliflozin) is an SGLT2 inhibitor used for type 2 diabetes and, in selected adults, for cardiovascular and kidney-risk reduction. Its benefits can extend beyond lowering blood sugar, particularly in people with established cardiovascular disease or diabetic kidney disease. However, safe prescribing requires attention to kidney function, hydration, foot health, infection risk, interacting medicines, and the possibility of ketoacidosis.
Invokana should be taken only according to an individualized prescription, not adjusted according to blood sugar readings alone. If you develop significant dehydration, genital or urinary infection symptoms, worsening foot problems, or possible ketoacidosis, seek medical advice promptly and review the treatment plan with your diabetes clinician.
Frequently Asked Questions
1. What is Invokana used for?
Invokana is used to improve blood sugar control in type 2 diabetes. In selected adults, it is also approved to reduce major cardiovascular events and certain kidney and heart-failure outcomes associated with diabetic nephropathy. Its suitability depends on kidney function and overall medical risk.
2. What is the usual dose of Invokana?
The usual labeled starting dose for glycemic control is 100 mg once daily before the first meal. Some patients with adequate kidney function may increase to 300 mg for additional glucose lowering. Cardiovascular and kidney-risk indications use 100 mg daily under current U.S. labeling.
3. Does Invokana cause weight loss?
Some people lose modest weight because canagliflozin causes glucose—and therefore calories—to be lost through urine. However, Invokana is not approved as a general weight-loss medicine. Weight effects should be considered alongside diabetes control, kidney health, hydration, and possible adverse effects.
4. What are the most common Invokana side effects?
Common adverse effects include female genital fungal infections, urinary tract infections, and increased urination. Dehydration, dizziness, and low blood pressure can also occur, especially in older adults or people using diuretics. New or persistent symptoms should be discussed with the prescriber.
5. Can Invokana cause ketoacidosis even if blood sugar is not very high?
Yes. SGLT2 inhibitor-associated ketoacidosis can occur with glucose levels that are lower than expected for typical diabetic ketoacidosis. Nausea, vomiting, abdominal pain, severe fatigue, or difficult breathing require urgent assessment, particularly during illness, fasting, dehydration, or insulin reduction.
6. Does Invokana still carry an amputation Boxed Warning?
No. The FDA removed canagliflozin's amputation Boxed Warning in 2020 after reviewing newer benefit-risk evidence. The potential lower-limb risk has not disappeared, however, and current labeling still recommends monitoring for foot infections, ulcers, and other lower-limb problems.

.png)




Comments